Pan-cancer AI-driven cell-free DNA sequencing platform for reducing disparities in early diagnosis, molecular characterization and surveillance of multiple cancer types

Awarded in 2024
Updated Apr 24, 2025

At a Glance

This project aims to address disparities in cancer outcomes by investigating the biology of cancers and the factors that contribute to aggressive cancers or lead to the development of treatment resistance. Researchers will introduce a minimally invasive liquid biopsy testing approach, which is essentially a blood draw, and utilize a new type of testing called fragmentomics to gather more information about a patient’s tumor and patterns of potential treatment resistance or cancer recurrence.